UBLYXI Trademark

Trademark Overview

On Thursday, October 18, 2018, a trademark application was filed for UBLYXI with the United States Patent and Trademark Office. The USPTO has given the UBLYXI trademark a serial number of 88160368. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 13, 2022. This trademark is owned by TG Therapeutics, Inc.. The UBLYXI trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations and substances for the treatment of oncological, autoimmune and central nervous system diseases and disorders
ublyxi

General Information

Serial Number88160368
Word MarkUBLYXI
Filing DateThursday, October 18, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 13, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 12, 2019

Trademark Statements

Goods and Servicespharmaceutical preparations and substances for the treatment of oncological, autoimmune and central nervous system diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 31, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTG Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10014
Party NameTG Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10014

Trademark Events

Event DateEvent Description
Monday, June 13, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 13, 2022ABANDONMENT - NO USE STATEMENT FILED
Saturday, November 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 5, 2021SOU EXTENSION 5 GRANTED
Monday, November 1, 2021SOU EXTENSION 5 FILED
Monday, November 1, 2021TEAS EXTENSION RECEIVED
Thursday, May 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 4, 2021SOU EXTENSION 4 GRANTED
Tuesday, May 4, 2021SOU EXTENSION 4 FILED
Tuesday, May 4, 2021TEAS EXTENSION RECEIVED
Thursday, February 11, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 10, 2021SOU EXTENSION 3 GRANTED
Monday, November 9, 2020SOU EXTENSION 3 FILED
Tuesday, February 9, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 11, 2020NOTICE OF REVIVAL - E-MAILED
Wednesday, November 11, 2020EXTENSION RECEIVED WITH TEAS PETITION
Wednesday, November 11, 2020PETITION TO REVIVE-GRANTED
Wednesday, November 11, 2020TEAS PETITION TO REVIVE RECEIVED
Thursday, May 7, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 5, 2020SOU EXTENSION 2 GRANTED
Tuesday, May 5, 2020SOU EXTENSION 2 FILED
Tuesday, May 5, 2020TEAS EXTENSION RECEIVED
Thursday, November 7, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 5, 2019SOU EXTENSION 1 GRANTED
Tuesday, November 5, 2019SOU EXTENSION 1 FILED
Tuesday, November 5, 2019TEAS EXTENSION RECEIVED
Tuesday, May 7, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 12, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 12, 2019PUBLISHED FOR OPPOSITION
Wednesday, February 20, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, January 28, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 28, 2019ASSIGNED TO EXAMINER
Wednesday, October 31, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 22, 2018NEW APPLICATION ENTERED

Related Keywords

ublyxi nervous system diseases disorders central autoimmune preparations substances treatment oncological